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Abstract
( )The expression of cytochromes P450 CYP in Barrett’s
esophagus and esophageal squamous mucosa was in-
vestigated. Esophagectomy specimens from 23 pa-
tients were examined for CYP expression of CYP1A2,
CYP3A4, CYP2C9/10, and CYP2E1 by immunohisto-
chemical analysis, and the expression of CYP1A1,
CYP3A4, CYP1B1, CYP2E1, and CYP2C9/10 in these
tissues was further confirmed by reverse transcription
polymerase chain reaction. Immunohistochemical anal-
( )ysis of esophageal squamous mucosa n s 12 showed
expression of CYP1A2, CYP3A4, CYP2E1, and CYP2C9/
10 proteins, but it was noted that cells within the basal
proliferative zone did not express CYPs. Immunohisto-
( )chemical analysis of Barrett’s esophagus n s 13
showed expression of CYP1A2, CYP3A4, CYP2E1, and
CYP2C9/10 that was prominent in the basal glandular
regions, which are areas containing a high percentage
of actively proliferating cells. Immunohistochemical
staining for both proliferating cell nuclear antigen and
the CYPs further supported the colocalization of CYP
expression to areas of active cell proliferation in Bar-
rett’s esophagus, whereas in the esophageal squamous
epithelium, CYP expression is limited to cells that are
not proliferating. RT-PCR with amplification product se-
quence analysis confirmed CYP1A1, CYP3A4, CYP1B1,
CYP2E1, and CYP2C9/10 mRNA expression in Barrett’s
esophagus. These data suggest that the potential abil-
ity of cells in Barrett’s esophagus to both activate
carcinogens and proliferate may be important risk fac-
tors affecting carcinogenesis in this metaplastic tissue.
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Introduction
Esophageal adenocarcinoma, which carries a very poor
prognosis, is now one of the 15 most prevalent cancers in
[ ]the United States 1–3 . Barrett’s esophagus is a metaplas-
[ ]tic columnar epithelium, with three histological subtypes 2
( )fundic, junctional, and intestinal that replaces the normal
squamous epithelium of the esophagus in 12% of patients
[ ]with gastroesophageal reflux disease 4 –6 . Barrett’s
esophagus is associated with an estimated 40-fold in-
creased risk for the development of esophageal adeno-
[ ]carcinoma 2 . It is the intestinal-type Barrett’s esophagus
that has been shown to be most closely associated with
[ ]adenocarcinoma development 3,7–10 . We have demon-
strated that Barrett’s esophagus and esophageal adenocar-
cinomas express the intestinal-specific, brush-border en-
[ ] [ ]zymes sucrase isomaltase 11 and aminopeptidase N 12 ,
providing strong evidence that intestinal-type Barrett’s
esophagus is not only histologically, but also biochemically
similar to the small intestine. However, unlike the small
intestine, which has a very low incidence of adeno-
carcinoma, Barrett’s esophagus is at high risk for develop-
ment into adenocarcinoma, although the reasons for this
are unknown.
One possible reason for the difference in the incidence of
cancer between the small intestine and Barrett’s esophagus
may lie in the expression of enzymes that can activate
( )carcinogens. The cytochromes P450 CYP are responsible
for the metabolism and detoxification of many xenobiotics
[ ]and endogenous compounds via oxidation 13–16 , and
these enzymes also may oxidize procarcinogens to reactive
electrophilic intermediates capable of inducing mutations.
Evidence also exists that CYP electrophilic metabolites can
[ ]serve as tumor promoters 17,18 . Aflatoxin, nitrosamines
such as N’ -nitrosonornicotine, and aromatic hydrocarbons
[ ]such as benzo a pyrene are examples of well-studied car-
cinogens present in tobacco and the diet that are activated
[ ]by specific forms of CYP enzymes 19–22 . These carcino-
gens have been specifically shown to induce cancers of the
[ ]esophagus in rodents 23 , and tobacco and alcohol use
have been shown to be risk factors for the development of
esophageal squamous carcinoma and possibly adeno-
[ ]carcinoma 24,25 .
The expression of specific forms of CYP proteins in
Barrett’s esophagus has not been described. CYP proteins
[ ]are expressed by cells in the villi of small intestine 26,27
and importantly, localization of CYP proteins within the gut
has demonstrated that they are limited to the more well
differentiated epithelial cells of the villi, away from areas of
[ ]active cell proliferation 26,28,29 . In the present studies, we
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examined whether Barrett’s esophagus expresses CYP en-
zymes and if the pattern of expression differs from that
present in the normal intestine or esophageal squamous
epithelium. The expression of six different CYP enzymes
was determined in normal esophageal squamous mucosa
and Barrett’s esophagus by using immunohistochemical
analysis and reverse transcription polymerase chain reac-
( )tion RT-PCR . The specific relationship in these tissues
between the proliferative compartment and the areas ex-
pressing CYP enzymes was determined using serial sec-
tions to compare areas expressing CYPs to areas express-
( )ing proliferating cell nuclear antigen PCNA .
Materials and Methods
Patients
After obtaining written consent, tissue was obtained from
(23 patients 21 men, 2 women; 22 whites, 1 African-Ameri-
)can who underwent esophagectomy at the University of
Michigan Medical Center from 1988 to 1995. High-grade
dysplasia was determined to be present by the final pathol-
( )ogy report of the surgical specimens from 11 patients 48% .
( )There were 18 78% specimens that contained an associ-
( )ated adenocarcinoma and 5 22% specimens without tu-
mors. The patients’ medical records were examined retro-
( ) ( )spectively. Twenty 87% were smokers, 18 78% drank
( )alcohol, and 17 74% of patients both smoke and drank
( )alcohol. Eight of the patients 35% were prescribed
( )omeprazole, and nine 39% were prescribed histamine
antagonists. None of the patients reported the use of other
medications known to affect the expression of CYPs. Se-
vere gastroesophageal reflux symptoms were present in 20
( )87% . None of the patients had undergone radiation or
chemotherapy.
Tissue
Specimens of normal esophagus and Barrett’s esopha-
gus were obtained immediately after esophagectomy and
(placed in Hank’s balanced salt solution Sigma Chemical
)Co, St. Louis, MO on ice for transportation to the labora-
tory. They were then quick frozen in liquid nitrogen and
maintained at -708C until time of assay. Tissues for immuno-
histochemical analysis were immediately fixed for 24 hours
in 10% formalin at room temperature, dehydrated in a series
of alcohols, and then processed in paraffin wax.
Antibodies
All anti-CYP antibodies were produced by Great Lakes
(Environmental and Biomedical Research GLEBR, Romeo,
)MI by immunization of rabbits with 200 mg of human
recombinant CYP proteins expressed in Escherichia coli
[ ] [ ]30 , as has been previously described 30–33 . The murine
( )anti-PCNA Dako, Carpinteria, CA has been previously
[ ]used in the analysis of Barrett’s esophagus 34 .
Conformation of Antibody Specificity
(Purified recombinant human CYP proteins 0.1 mg per
) ( )lane expressed in E coli, and total protein 10 mg per lane
extract from human liver microsomes. Microsomes were
prepared from liver samples obtained from Tennessee Donor
[ ]Services, Nashville, TN, as previously described 35 . The
liver microsomes, previously shown to express multiple CYP
[ ]isoforms 36 , were size-fractionated by sodium dodecyl
( )sulfate-polyacrylamide gel electrophoresis SDS-PAGE and
transferred to nylon membranes. The membranes were
probed individually with a 1:1000 dilution of each of the
polyclonal antibodies. Immunoreactivity was detected with
an alkaline phosphatase–conjugated, donkey anti-rabbit IgG
(secondary antibody Jackson ImmunoResearch Laboratory,
)Inc, West Grove, PA and developed with a substrate mix-
ture containing 5-bromo-4-chloro-3-indolyl phosphate,
p-toluidine, and nitroblue tetrazolium.
Immunohistochemistry
Formalin-fixed, paraffin-embedded specimens were sec-
tioned at 5 mm and placed on poly-l-lysine–treated slides.
The slides were then deparaffinized in two changes of
( )xylene 20 minutes each and then rehydrated down an
alcohol gradient. Endogenous peroxidase activity was
( )quenched with 2 changes 20 min each of 0.3% hydrogen
( )peroxide in phosphate-buffered saline PBS . For immuno-
staining with the anti-CYP3A4, anti-CYP1A2, anti-CYP2C9/
10, and anti-CYP2E1 antibodies, nonspecific binding was
( )blocked with undiluted goat serum 30 minutes ; for
anti-PCNA immunostaining, nonspecific binding was blocked
with 1:20 horse serum in PBS-1% bovine serum albumin
( ) ( )BSA 30 minutes . Incubations of primary antibodies were
performed at 48C overnight at the following dilutions in
)PBS-1% BSA: 1 Anti-CYP1A2 and anti-CYP3A4 antibody,
) )1:200 dilution; 2 anti-CYP2E1 antibody, 1:300 dilution; 3
)anti-CYP2C9/10 antibody, 1:100 dilution; and 4 anti-PCNA
antibody, 1:100 dilution. A section of tissue on each slide
received only PBS-BSA and no primary antibody and served
to identify potential nonspecific immunostaining. Immunore-
activity was developed with the species-appropriate Vectas-
( )tain detection kit Vector, Burlingame, CA per the manufac-
turers recommendations. The reactions with the chro-
( )mogens 3,3’-diaminobenzidine Sigma Chemical Co or
( )aminoethylcarbazole Sigma Chemical Co at 0.1 mg/mL
dissolved in PBS were monitored by using light microscopy
and quenched in distilled water, and then the sections then
lightly counterstained with Harris modified hematoxylin. The
slides were then dehydrated up an alcohol gradient and
permanently mounted before examination under light mi-
croscopy by three independent observers. The amount of
immunoreactivity in each sample was assessed and given a
number as follows: 0 if no staining was present or 1, 2, or 3
based upon intensity of staining. The localization of staining
in the tissues was also recorded.
Reverse Transcription Polymerase Chain Reaction
The expression of CYP1A1, CYP3A4, CYP1B1, CYP2E1,
and CYP2C mRNAs was determined by PCR by using
[ ]reverse transcribed total RNA, as previously described 11 .
Ten micrograms of total RNA was reverse transcribed into
(cDNA using random hexamer primers 125 pmol/ reaction,
)Promega, Madison, WI in a solution containing 50 mmol/L
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( )Tris HCl pH 8.3 , 50 mmol/L KCl, 8 mmol/L MgCl , 102
mmol/L dithiothreitol, and 1 mmol/L each of dATP, dCTP,
dGTP, and dTTP in a total volume of 25 mL. The reaction
mixture was heated to 658C for 5 minutes, cooled to 418C,
and avian myeloblastosis virus reverse transcriptase was
(added 7 units per reaction, Boehringer Mannheim, Indi-
)anapolis, IN . The reaction was allowed to proceed for 1
hour at 418C.
After first-strand cDNA generation, PCR amplification was
done with 5 mL of RT-PCR product added to a mixture of 10
mmol/L Tris HCl; pH 8.3, 50 mmol/L KCl; 2.5 mmol/L
(MgCl or 1.5 mmol/L for CYP1B1 and CYP3A4 primer2
)sets ; 0.2 mmol/L each of dATP, dGTP, dCTP, and TTP;
0.25 pmol/L of each primer; and 0.625 units of Taq DNA
polymerase, in a final reaction volume of 25 mL. The reac-
tion mixture was initially heated to 958C for 30 seconds
before 35 thermal cycles with each cycle consisting of 958C
for 15 seconds, 608C for 30 seconds, and 728C for 30
seconds, followed by an incubation for 7 minutes at 728C.
The primer sets for CYP enzyme are as follows:
( )CYP Primers Product bp Reference
[ ]1A1 Forward: 5’-TCACAGAC- 432 37
AGCCTCATTCAC-3’
Reverse: 5’-GATGGGTTGAC-
CCATAGCTT-3’
[ ]1B1 Forward: 5’-ACCCCCAG- 313 38
TCTCAATCTCAAC-3’
Reverse: 5’-CGTTCGGGCTG-
AGGCTGGTGC-3’
[ ]2C Forward: 5’-GCTAAAGTC- 332 37
CAGGAAGAGATTGA-3’
Reverse: 5’-TCCTGCTGAGA-
AAGGCATGAAGT-3’
[ ]2E1 Forward: 5’-AGCACAAC- 365 37
TCTGAGATATGG-3’
Reverse: 5’-ATAGTCACTGT-
ACTTGAACT-3’
[ ]3A4 Forward: 5’-AACCTGGCT- 353 37
TCTCCTGGCTGTCAG-3’
Reverse: 5’-ATCTCTTCCATT-
CTTCATCCTCAGCT-3’
All primer pairs produce amplification products that span
introns to control for potential DNA contamination. The
amplification of ubiquitin served as a control for mRNA
[ ]integrity 11 . The PCR amplification products were ana-
lyzed on 1.8% agarose gels containing ethidium bromide.
The PCR amplification products were purified with Micro-
( )con-100 Amicon, Beverly, MA centrifugal concentrators,
and sequence analysis was performed with an ABI Prism
(377 DNA Sequencer PE Applied Biosystems, Foster City,
)CA .
Western Blot Analysis
Total tissue protein was extracted in a buffer containing
[ ]Nonidet P-40 as previously described 39 . One hundred
micrograms of total protein extract was fractionated by 12%
SDS-PAGE and transferred to nylon membranes. The iso-
forms of CYP protein were detected with the anti-CYP1A2,
anti-CYP3A4, anti-CYP2C9/10, and anti-CYP2E1 antibod-
ies at 1:1000 dilutions, followed by incubation with a peroxi-
dase-conjugated secondary antibody at a 1:10000 dilution
( ) (Sigma . Enhanced chemiluminescence Pierce, Rockford,
) ( )IL and Hyperfilm Amersham, Arlington Heights, IL were
used for detection. Loading of total protein was evaluated
by commassie blue staining of acrylamide gels.
Results
Conformation of Antibody CYP Isoform Specificity
Western blot analysis with polyclonal anti-CYP antibodies
was used to probe membranes containing 0.1 mg of recom-
Figure 1. SDS -PAGE of purified recombinant human CYP proteins
expressed in E coli and human liver microsome protein extracts known
[ ]to contain high concentrations of human CYP 36 . Western blot analy-
sis of this membrane using the anti-CYP3A4 antibody, anti -CYP1A2
antibody, anti -CYP2C10 antibody, and anti-CYP2E1 antibody demon-
strates isoform specificity for each of these antibodies. The anti-
CYP2C10 antibody slightly cross- reacts with CYP1A1 protein. A sec-
ond band of approximately 40 kDa is present in the lane containing
recombinant CYP3A4, and this band also is recognized by the
anti-CYP3A4 antibody. None of the anti -CYP antibodies cross- react
with other proteins expressed in human liver microsomes.
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Figure 3. Photomicrographs of esophageal tissues immunostained with an anti-CYP2E1 antibody showing expression of CYP2E1 in the superficial
( ) ( ) ( ) ( )squamous cells s and not in the proliferative zone arrows of esophageal squamous epithelium A . However, in Barrett’s columnar metaplasia B ,
( ) ( )CYP2E1 is primarily expressed by cells constituting the glandular regions g , which are areas of active cell proliferation arrows . A similar pattern of
( ) ( )expression of CYP2C9/10 in esophageal squamous epithelium C and Barrett’s metaplasia D tissues is shown by immunostaining with an
( )anti-CYP2C9/10 antibody. Original magnifications = 100 .
binant human CYP1A1, CYP1A2, CYP3A4, CYP2C9/10,
CYP2E1, CYP2D6, and three individual human liver micro-
( )somal protein preparations Figure 1 . These analyses
showed isoform specific bands of approximately 50 kDa for
each antibody. The anti-CYP3A4 antibody also reacted with
an approximately 40 kDa protein that was apparent in the
purified CYP3A4 protein preparation. This may represent a
contaminant or a truncated form of the CYP3A4 protein.
The anti-CYP2C9/10 antibody cross-reacted slightly with
CYP1A1. None of the antibodies significantly cross-reacted
with other proteins present in human liver microsomes.
Identification of Areas of Active Cell Proliferation within
Esophageal Squamous Mucosa and Barrett’s Esophagus
Immunohistochemistry with the anti-PCNA antibody on
sections of esophageal squamous mucosa and Barrett’s
esophagus specimens showed nuclear staining in 100% of
( ) ( )the specimens n s 14 examined Figure 2A, B . In
Barrett’s esophagus, intense nuclear staining was observed
in a high percentage of cells within the basal glandular
regions, but a few cells within the villi also stained positively
for PCNA expression. Squamous epithelium showed in-
tense nuclear staining within a high percentage of cells
( ) ( )Figure 2. Photomicrographs of sections of esophageal squamous mucosa A and intestinal-type Barrett’s metaplasia B after immunohistochemical
( )staining with an anti-PCNA antibody showing nuclear staining of cells within these tissues that are actively proliferating arrows . In the esophageal
squamous mucosa, cell proliferation is limited to the most basal cell regions. In Barrett’s metaplasia, cell proliferation is primarily located in the basal
( ) ( )glandular regions of the tissue and some of the cells constituting lower portions of the villi v . C A section of terminal ileum following immunohisto-
( ) ( )chemical staining with an anti-CYP3A4 antibody demonstrates cytoplasmic expression of CYP3A4 along the tips of the villi v and not in the crypts c ,
( ) ( )which are the areas of active cell proliferation arrows within the small intestine. D Esophageal squamous mucosa expresses CYP3A4, and, similar to
( ) ( )the small intestine, cells within the basal areas of active proliferation arrows do not express CYP3A4. In contrast, E an area of esophagus with
intestinal-type Barrett’s metaplasia shows expression of CYP3A4 in the basal glandular region, which also show a high percentage of actively
( ) ( ) ( )proliferating cells arrows by positive immunostaining with the anti-PCNA antibody in a near-serial section F . Mitotic figures are also visible m . The
( )esophageal squamous epithelium s , which flanks this intestinal metaplasia, however, does not express CYP3A4 in areas of active cell proliferation
( ) ( ) ( )arrow . G Immunohistochemical analysis of esophageal squamous mucosa and H intestinal-type Barrett’s metaplasia with an anti-CYP1A2 antibody
( )showing a similar pattern of expression of the CYP1A2 isotype with intense staining of the glandular regions g of the intestinal-type metaplasia but not
( )in the proliferative zone of the squamous mucosa. Arrows denote areas of active cell proliferation. Original magnifications = 100 .
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within the basal, proliferative cell layer, with no staining
detected in cell nuclei superficial to this. These patterns of
PCNA expression in esophageal squamous mucosa and
[ ]Barrett’s esophagus have been previously described 34
and demonstrate the areas of active cell proliferation within
these tissues.
Immunohistochemical Analysis of CYP1A2, CYP2C9/10,
CYP2E1, and CYP3A4 Expression
Immunohistochemical analysis using an anti-CYP3A4 an-
tibody showed expression of CYP3A4 protein in a specimen
of terminal ileum mucosa, 100% of specimens of intes-
( )tinal-type Barrett’s esophagus n s 13 , and 100% of
( )specimens of squamous epithelium n s 12 examined.
The localization and pattern of immunostaining, however,
(differed among these types of epithelium Figures 2C, D
)and E . In the terminal ileum, epithelial cells along the tips of
the villi expressed CYP3A4 protein, but cells within the
( )region of active cell proliferation crypts did not. The detec-
tion of CYP3A4 with this antibody is consistent with the
[ ]known distribution of CYP3A4 in this tissue 31 . Similarly,
the esophageal squamous mucosa stained homogeneously
for CYP3A4 protein expression with the exception of cells
constituting the proliferative zone along the basement mem-
brane, which do not express the CYP3A4 protein. In con-
trast, Barrett’s metaplastic columnar epithelium expressed
CYP3A4 protein throughout the tissue including the basal,
glandular regions that are areas of active cell proliferation
[ ]34 . In fact, these glandular regions of the metaplastic
epithelium appeared to stain more intensely than the villi in
53% of the samples examined. The separation of CYP3A4
expression and PCNA expression found in esophageal
squamous mucosa differed significantly from the colocaliza-
tion of CYP3A4 expression and PCNA expression observed
in intestinal-type Barrett’s metaplasia. Near-serial sections
of a region containing both types of epithelium and stained
Figure 4. Examination of the expression of mRNA for the CYP1A1 gene
by using RT-PCR in specimens of normal esophageal squamous mu-
( ) ( )cosa N , normal gastric mucosa G , and Barrett’s esophagus mucosa
( )B from the same patients. Primers for the human CYP1A1 gene were
used, which produce an expected 237-bp product. The integrity of the
mRNA is shown by the ability to amplify a 219-bp ubiquitin control gene
by RT-PCR.
Table 1. RT-PCR Analysis of CYP mRNA Expression.
Number of Samples With RT-PCR Product
Tissues CYP1A1 CYP3A4 CYP1B1 CYP2E1 CYP2C
Esophageal 5/7 7/7 7/7 7/7 6/7
squamous
Barrett’s 7/7 7/7 6/7 7/7 7/7
esophagus
( )for either CYP3A4 or PCNA expression Figure 2E,F , clearly
demonstrate the expression of CYP3A4 in proliferating cells
in Barrett’s mucosa but not in the esophageal squamous
epithelium. No differences were observed in either the inten-
sity or the localization of CYP3A4 staining between speci-
mens from patients based on prior use of tobacco, ethanol,
and/or histamine antagonists/omeprazole. Immunohisto-
chemical analysis of the esophageal tissues with the anti-
( )CYP1A2 Figure 2G,H , anti-CYP2E1, and anti-CYP2C9/10
( )Figure 3 antibodies showed identical results to those ob-
tained with the anti-CYP3A4 antibody. Thus, like epithelial
cells from the small intestine and esophageal squamous
mucosa, intestinal-type Barrett’s metaplastic cells express
multiple isoforms of CYP. Importantly, this expression of
CYPs in Barrett’s esophagus colocalizes to areas of active
cell proliferation, thus differing from the normal tissues ex-
amined in which the regions of active cell proliferation did
not express CYPs.
RT-PCR Analysis of CYP1A1, CYP1B1, CYP2E1, and
CYP2C9/10 mRNA Expression
To confirm the expression of CYPs by Barrett’s eso-
phagus, the expression of CYP1A1, CYP3A4, CYP1B1,
CYP2E1, and CYP2C9/10 mRNA was analyzed with
RT-PCR. Amplification with specific primers for CYP1A1
produced the expected 237-bp band in all nine samples of
( )Barrett’s esophagus examined Figure 4 . The CYP1A1
RT-PCR product was also detected in some normal squa-
mous epithelium as expected and weakly in the gastric
[ ]mucosa samples 26,37 . The integrity of the mRNA was
confirmed in each sample by RT-PCR of ubiquitin, which
was identified as a 219 bp product. The amplification prod-
ucts obtained with the CYP1A1, CYP1B1, CYP2E1, and
CYP3A4 primer pairs shared 100% homology with the pre-
( )dicted sequences Genbank of these CYP isoforms. Se-
quence analysis of the amplification product obtained with
the CYP2C primer pair identified small regions of degenera-
tive sequence, suggesting amplification of the isoforms from
the CYP2C family in addition to CYP2C9/10 including
CYP2C18, CYP2C19, and CYP2C8. Results of amplifica-
tions in normal esophagus and the Barrett’s mucosa from
the same patients using primers specific for the coding
sequences of these CYP isoenzymes are summarized in
Table 1.
Western Blot Analysis of CYP1A2, CYP2C9/10, CYP2E1,
and CYP3A4 Protein
Western blot analysis of total tissue protein extracts from
normal squamous esophagus and Barrett’s esophagus was
performed to further confirm CYP protein expression in
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Figure 5. Western blot analysis of total protein extracts from normal
squamous and Barrett’s esophagus showing CYP1A2, CYP3A4,
CYP2C9/10, and CYP2E1 proteins in these tissues. Purified recombi-
nant CYP isoforms served as positive controls. The bacterial source of
these recombinant proteins results in subtle migration differences com-
pared with the proteins from tissue extracts.
( )these tissues Figure 5 . CYP proteins of appropriate rela-
( )tive molecular mass Mr were detected in both normal
squamous and Barrett’s esophagus specimens by using the
anti-CYP1A2, anti-CYP3A4, anti-CYP2C9/10, and anti-
CYP2E1 antibodies. The identification of immunoreactive
proteins of the expected Mr indicates the staining observed
in the immunohistochemical studies is specific for CYP
proteins.
Discussion
The major risk factor for development of adenocarcinoma of
the esophagus is the presence of the intestinal-type Barrett’s
esophagus. Why this subtype of Barrett’s esophagus is at
high risk to develop dysplasia and progress to invasive
adenocarcinoma is unknown. This study demonstrates that
Barrett’s esophagus expresses multiple CYP isoenzymes
that are necessary to activate a number of potential carcino-
gens. This is the first description of expression of CYP
enzymes in this important metaplastic mucosa.
We found that Barrett’s esophagus has a different cellu-
lar distribution pattern of CYP enzyme expression, com-
pared with either the small intestine or squamous
esophageal mucosa. In Barrett’s esophagus, the most in-
tense staining was present within cells in basal glandular
structures that are areas of active cell proliferation. The
expression of CYP1A2, CYP3A4, and CYP2E1 isoenzymes,
three forms known to activate carcinogens in cells that are
[ ] (actively proliferating 14,15 the CYP2C9/10 enzyme is not
[ ])known to activate carcinogens 15 , may be a critical differ-
ence between normal tissues that express CYPs and Bar-
rett’s esophagus. In normal tissues of the gut, the cells that
express CYP1A2 and CYP3A4 enzymes and are thus capa-
ble of carcinogen activation are confined within the nonpro-
liferating, well-differentiated regions. These cells are also
regularly shed into the esophageal or intestinal lumen, and
therefore cells that may sustain DNA damage by CYPs-
activated carcinogens, may not pose a carcinogenic threat
[ ]28,29 . In contrast, the metaplastic cells within the basal,
glandular regions of Barrett’s esophagus that can both ac-
tively proliferate and express CYP1A2, CYP3A4, and
CYP2E1 may be more likely to sustain genetic damage
from activated carcinogens and progress towards dysplasia
and adenocarcinoma.
The expression of CYPs by Barrett’s esophagus was
expected. The inducible and constitutive expression of CYP
isoenzymes in the normal gut likely serves a vital protective
[ ]role from ingested toxins 28,29,41 , and the expression of
CYPs in Barrett’s esophagus likely serves a similar role.
The distal esophagus of patients with Barrett’s esophagus is
chronically bathed by enteric contents, increasing exposure
time to ingested toxins and possibly inducing the expression
of CYPs. In addition, the pharmacological treatment of
symptoms from gastroesophageal reflux with omeprazole
and/or histamine antagonists may induce CYP expression
in Barrett’s esophagus, as 74% of the patients in this study
were taking one of these drugs. Finally, tobacco use is
[ ]known to induce CYP1A1 expression in the lungs 42 , and
87% of the patients in this study smoked; alcohol is known
to induce CYP2E1 expression, and alcohol was consumed
regularly by 78% of these patients. However, constitutive
expression of these CYP isoforms was identified in speci-
mens of normal squamous and Barrett’s esophagus from
patients who denied alcohol, tobacco, and histamine antag-
onists/omeprazole exposure.
The expression of CYPs by Barrett’s esophagus may
provide a selective advantage. Cells expressing CYPs may
be more resistant to damage and death in the hostile
environment created by chronic reflux of enteric contents.
For this epithelium to regenerate after ulceration, these
same cells would need to be capable of proliferation. This
mechanism could underlie some of the selection factors that
lead to the replacement of squamous cells by Barrett’s
esophagus after ulceration, and may explain why there is
expression of CYPs by Barrett’s epithelium in cells within
deep glandular structures that actively proliferate.
The presence of CYPs in Barrett’s esophagus suggests a
potential role for CYP-dependent activation of carcinogens
in the development of adenocarcinoma of the esophagus.
An approximately twofold increased risk of adenocarcinoma
[ ]of the esophagus associated with tobacco use 24,25 , and
at least a subgroup of p53 mutations detected in esophageal
adenocarcinoma, may implicate CYP-activated carcinogens
[ ]43 . Mutational analysis of the p53 gene in esophageal
adenocarcinoma showed G:C to T:A transversions in 20%
[ ]of the adenocarcinomas examined 43 . Importantly, muta-
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tion and/or loss of wild-type p53 allele is a frequent and
early event in the development of esophageal adenocarci-
[ ]nomas 44,45 . These findings suggest that CYP-activated
carcinogens may be involved in the pathogenesis of at least
a subset of Barrett’s esophagus adenocarcinomas.
Our study confirms the previous findings of CYP1A1,
CYP1A2, and CYP3A4 expression in normal human eso-
[ ]phagus 26,40 and further describes apparently constitu-
tive expression of CYP2C9/10 and CYP2E1 in normal
esophageal squamous epithelium and Barrett’s esophagus.
Previous studies have used immunohistochemistry or in situ
hybridization to localize CYP expression within the esopha-
gus and the small intestine and demonstrate expression
primarily in the well-differentiated cells closer to the luminal
(surface tips of villi in the small intestine, flattened squa-
) [ ]mous cells of the esophagus 26–29 . Our findings also
confirm these previous studies in esophageal squamous
mucosa.
This study identified CYP protein expression by immuno-
histochemistry and Western blot analysis and examined
CYP mRNA expression by RT-PCR. Confirmation of CYP
expression by bioassay showing specific catalytic activity
would further support expression of these CYP isoforms,
however, the quantity of tissue necessary for these assays
precludes their use on human surgical specimens.
In summary, we have demonstrated the expression
of CYP isoenzymes in Barrett’s epithelium. Cells within
Barrett’s esophagus that are actively proliferating express
CYP1A2 and CYP3A4, differing from the small intestine and
normal esophageal mucosa, which lack expression of these
isoenzymes in proliferating cells. This potential ability to
activate procarcinogens within cells that actively proliferate
may be one reason Barrett’s esophagus is prone to the
development of dysplasia and adenocarcinoma.
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